ID: ALA3342219
Max Phase: Preclinical
Molecular Formula: C41H46N2O19S
Molecular Weight: 902.88
Molecule Type: Small molecule
Associated Items:
ID: ALA3342219
Max Phase: Preclinical
Molecular Formula: C41H46N2O19S
Molecular Weight: 902.88
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)=CC(=O)O[C@H]1C(=O)O[C@@H]2C[C@H]3C(C)=C(O)C(=O)C[C@]3(C)[C@H]3[C@@H](O)[C@H](OC(=O)CCC(=O)OCCCCOc4no[n+]([O-])c4S(=O)(=O)c4ccccc4)[C@]4(C(=O)O)OC[C@]32[C@@H]14
Standard InChI: InChI=1S/C41H46N2O19S/c1-20(2)16-28(47)60-31-33-40-19-58-41(33,38(51)52)34(30(49)32(40)39(4)18-24(44)29(48)21(3)23(39)17-25(40)59-37(31)50)61-27(46)13-12-26(45)56-14-8-9-15-57-35-36(43(53)62-42-35)63(54,55)22-10-6-5-7-11-22/h5-7,10-11,16,23,25,30-34,48-49H,8-9,12-15,17-19H2,1-4H3,(H,51,52)/t23-,25+,30+,31+,32+,33+,34-,39-,40+,41+/m0/s1
Standard InChI Key: XQBLIAUJCLVIRE-MPGCPKSBSA-N
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 902.88 | Molecular Weight (Monoisotopic): 902.2415 | AlogP: 1.62 | #Rotatable Bonds: 15 |
Polar Surface Area: 305.60 | Molecular Species: ACID | HBA: 19 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 21 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.34 | CX Basic pKa: | CX LogP: 0.63 | CX LogD: -2.93 |
Aromatic Rings: 2 | Heavy Atoms: 63 | QED Weighted: 0.08 | Np Likeness Score: 1.71 |
1. Tang W, Xie J, Xu S, Lv H, Lin M, Yuan S, Bai J, Hou Q, Yu S.. (2014) Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies., 57 (18): [PMID:25179783] [10.1021/jm5007534] |
Source(1):